Envafolimab
- Generic Name
- Envafolimab
- Drug Type
- Biotech
- CAS Number
- 2102192-68-5
- Unique Ingredient Identifier
- ES1M06M6QH
- Indication
用于不可切除或转移性微卫星高度不稳定（MSI-H）或错配修复基因缺陷型（dMMR）的成人晚期实体瘤患者的治疗，包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Target Recruit Count
- 20
- Registration Number
- NCT05298020
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
- Conditions
- Metastatic or Recurrent Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Liangjun Zhu M.M.
- Target Recruit Count
- 38
- Registration Number
- NCT05237349
- Locations
- 🇨🇳
Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)
- Conditions
- MSS Locally Advanced Rectal Adenocarcinoma
- Interventions
- Radiation: Short-course RadiationProcedure: TME surgery, total mesorectal excision
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT05216653
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 39
- Registration Number
- NCT05213221
- Locations
- 🇨🇳
the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- The First People's Hospital of Lianyungang
- Target Recruit Count
- 40
- Registration Number
- NCT05203276
- Locations
- 🇨🇳
The First People'S Hospital of Lainyungang, Lianyungang, Jiangsu, China
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
- Conditions
- Advanced Endometrial Cancer
- Interventions
- Drug: Envafolimab+Lenvatinib
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05112991
- Locations
- 🇨🇳
Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05068427
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China
Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC
- Conditions
- Non-small Cell Lung Cancer Stage IV
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2021-09-24
- Target Recruit Count
- 20
- Registration Number
- NCT05055167
- Locations
- 🇨🇳
First affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
- Conditions
- Biliary Tract Neoplasms
- Interventions
- Drug: Gemcitabine&Cisplatin
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT04910386
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT04891198
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.